Could it be that if current volume production run/testing goes well that near term IP sales (licences, royalties) might be contingent on that outcome? The design is not much use to large companies if it (or the bits they need) can't be produced in large amounts efficiently and at a high level of quality assurance.
- Forums
- ASX - By Stock
- 2021 BRN Discussion
Could it be that if current volume production run/testing goes...
-
- There are more pages in this discussion • 21,873 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BRN (ASX) to my watchlist
(20min delay)
|
|||||
Last
28.0¢ |
Change
-0.015(5.08%) |
Mkt cap ! $552.2M |
Open | High | Low | Value | Volume |
29.5¢ | 30.0¢ | 27.5¢ | $6.297M | 22.13M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
44 | 1370975 | 27.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
28.5¢ | 1073647 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
43 | 1320975 | 0.275 |
48 | 1391142 | 0.270 |
14 | 575137 | 0.265 |
16 | 333306 | 0.260 |
7 | 126883 | 0.255 |
Price($) | Vol. | No. |
---|---|---|
0.285 | 1073647 | 14 |
0.290 | 678311 | 14 |
0.295 | 941871 | 17 |
0.300 | 1088061 | 27 |
0.305 | 934255 | 14 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
BRN (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online